Obestatin
ghrelin-associated peptide (GAP), preproghrelin (76-98), obestatin (1-23)
Obestatin is a 23-amino-acid amidated peptide cut from the same precursor protein as ghrelin. It was announced in Science in 2005 as an anti-ghrelin hormone that suppressed food intake and acted through the receptor GPR39. Both of those claims subsequently failed independent replication, and the original authors themselves reported that their peptide preparation had been contaminated. It remains a real peptide of uncertain function and is a useful case study in how a high-profile finding can unravel.
Mechanism
Obestatin is encoded within the GHRL gene as part of preproghrelin, downstream of the ghrelin sequence, and is generated by prohormone convertase cleavage followed by C-terminal amidation. That much is not in dispute. The peptide exists, is produced in the stomach and can be detected in circulation, and immunoreactivity has been mapped in gastric and pancreatic tissue.
The proposed mechanism is where things collapse. The 2005 Science paper reported that obestatin bound and activated GPR39, an orphan G-protein-coupled receptor in the ghrelin receptor family, and that this mediated suppression of food intake, inhibition of jejunal contraction and reduced weight gain. Independent groups then showed that GPR39 is a zinc-sensing receptor activated by Zn2+ ions and not by obestatin, and could not reproduce obestatin binding or downstream signalling. A technical comment in Science reported that radiolabelled obestatin does not bind GPR39, and the original authors acknowledged that their peptide preparation had been contaminated and that the in vitro receptor findings could not be reproduced with purified obestatin. GPR39 has since been characterised as a zinc receptor with roles in pancreatic, gastrointestinal and neuronal function, unrelated to obestatin. Obestatin therefore has no validated receptor. Various later papers report effects on adipocytes, pancreatic beta cells, cardiomyocytes and skeletal muscle fibre type, but these lack a coherent receptor mechanism and have not converged.
What the research shows
Zhang and colleagues reported in Science in 2005 that obestatin, derived from the ghrelin precursor, suppressed food intake, inhibited jejunal contraction and decreased body weight gain in rats, acting via GPR39. The paper was widely covered and generated substantial commercial interest in obestatin as an obesity target.
The receptor claim collapsed quickly. Holst and colleagues showed in Endocrinology in 2007 that GPR39 signalling is stimulated by zinc ions and that obestatin had no reproducible effect, concluding GPR39 is probably not the obestatin receptor. A technical comment in Science by Chartrel and colleagues reported that radiolabelled obestatin does not bind GPR39-expressing cells; in response, the original authors reported that their peptide preparation had been contaminated and that the in vitro findings did not reproduce with purified obestatin. Gourcerol, St-Pierre and Taché reviewed the functional evidence in Regulatory Peptides in 2007 and proposed the peptide be renamed ghrelin-associated peptide, since 'obestatin' encodes a claim about obesity that the data do not support.
The picture is not perfectly uniform, and honesty requires saying so: a 2010 peptide-chemistry study by Subasinghage and colleagues in Peptides reported that full-length obestatin and an {11-23} fragment did reduce food intake in their rodent model and lowered post-meal glucose, correlating with alpha-helical structure. That is a single study against several failed replications of the central claim, and it does not restore the receptor mechanism. What survives overall is a genuine peptide with genuine tissue expression, detectable in human plasma, whose physiological role is unknown, with no validated receptor, no reliably replicated physiological function and not a single human trial. Anyone encountering obestatin marketed for appetite suppression or fat loss should know that the specific claim being made is the one that failed replication most decisively.
Evidence assessment
Preclinical only
There are no controlled human trials of obestatin administration for any indication. Every citation in this record is cell-culture, receptor-pharmacology or rodent work. The headline animal finding (suppression of food intake) and the proposed receptor both failed replication in independent laboratories, though at least one later rodent study did report a food-intake effect, so the preclinical literature is not entirely one-directional. Human data are limited to observational measurements of circulating obestatin and obestatin-to-ghrelin ratios, which are association studies of unclear meaning. All-preclinical citations means tier 'preclinical'.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake Preclinical only
Reported that obestatin suppressed food intake, inhibited jejunal contraction and reduced weight gain in rats via GPR39. The original claim; both the functional and receptor findings were subsequently shown not to replicate, and the authors later reported preparation contamination.
GPR39 signaling is stimulated by zinc ions but not by obestatin Preclinical only
Zinc ions activate GPR39 through inositol phosphate turnover and cAMP production, whereas obestatin had no reproducible effect. The authors concluded GPR39 is probably not the obestatin receptor, reframing it as a zinc-sensing receptor.
Comment on 'Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake' Preclinical only
Reported that radiolabelled obestatin does not bind GPR39 and that no effects of obestatin on GPR39-transfected cells were observed. In response the original authors reported their peptide preparation had been contaminated and that the in vitro findings did not reproduce with purified obestatin.
Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Preclinical only
Concluded that obestatin is unlikely to be the endogenous ligand for GPR39, given absent specific binding and no signal transduction in GPR39-expressing cells, and that obestatin failed to influence food intake or gastric transit in animal models, prompting the proposal to rename the peptide.
Metabolic and structural properties of human obestatin {1-23} and two fragment peptides Preclinical only
Reported that full-length obestatin and the {11-23} fragment reduced food intake (86 and 90 per cent respectively) and lowered post-meal glucose, while the {1-10} fragment had no metabolic effect; alpha-helical structure correlated with activity. This result runs counter to the replication failures elsewhere in this record and is presented as such rather than harmonised away.
Safety
There is no human safety dataset for obestatin, because no clinical trial of obestatin administration has been conducted. Nothing is known about its effects in humans at any dose, by any route, over any duration. Obestatin sold as a research chemical carries the standard and substantial risks of that market: no pharmacopoeial identity testing, unverified purity, potential bacterial endotoxin contamination in material not manufactured to sterile injectable standards, and no manufacturing oversight. The specific irony worth noting is that contamination of a peptide preparation is precisely what produced the original obestatin findings in the first place, an object lesson in what unverified peptide material can do to a result. Given no validated receptor, no reliably replicated function and no human data, there is no scientific basis on which to use obestatin for any purpose outside a laboratory.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No UK marketing authorisation and no licensed product. Obestatin is legitimately supplied only as a laboratory research chemical. Any obestatin offered for human use in the UK is an unlicensed medicinal product being sold outside the regulatory system, with no efficacy evidence to support the claims typically made for it. |
| United States | Not an approved medicine and not under clinical development for any indication. Available only as a research reagent. It is not a dietary supplement ingredient and marketing it for human consumption would be unlawful. |
| WADA (sport) | Not listed by name on the WADA Prohibited List and not a growth hormone secretagogue. However, athletes should be aware that research chemicals sold under peptide names are frequently mislabelled or contaminated, which creates a real inadvertent-doping risk independent of the named substance's status. |
Questions
The weight of evidence says no. That was the original 2005 claim, and independent laboratories could not reproduce it; the proposed receptor was disproved and the original authors reported their peptide preparation had been contaminated. One later rodent study did report reduced food intake, so the preclinical literature is not unanimous. But there has never been a human trial, and marketing that describes obestatin as a proven appetite suppressant is well ahead of the evidence.
None that has been validated. GPR39 was proposed in the original paper but was subsequently shown to be a zinc-sensing receptor that is not activated by obestatin, and the original authors conceded their peptide preparation had been contaminated. Two decades on, obestatin has no established receptor.
That was the premise of the name and the original paper. It is not supported. The two peptides come from the same precursor gene, but obestatin has not been shown to oppose ghrelin's actions in any reliably replicated way. Researchers proposed renaming it ghrelin-associated peptide for exactly this reason.
Only observational: studies measuring circulating obestatin concentrations, or obestatin-to-ghrelin ratios, in conditions such as ulcerative colitis, obesity and diabetes. These are associations with unclear meaning, complicated by concerns about assay specificity. No one has ever administered obestatin to humans in a controlled trial.